- News
News
Welcome to the homepage of AIHTA!
AIHTA is an academic non-profit institute. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the AIHTA team.
In the News section you will find our most recent publications: newsletter, project-reports etc. Previous reports you might find via Research areas, Research projects and Repository.
Announcement
Sponsoring Austrian CME/ continuing medical education for physicians. A systematic analysis of the CME-Database
In recent years, the sponsorship of CME/ continuing medical education for physicians by the pharmaceutical and medical device industry is increasingly scrutinized. The question in this project was the scope of sponsoring in the Austrian CME-training. From the CME database of the Austrian Academy of doctors 13 medical fields (from a total of 56) were selected with the aim to analyse the number of events that were financially supported by manufacturer. The investigation shows that a sponsorship of at least 14.3% and at most 67.2% of the events took place. The sponsors are, as might be expected, pharmaceutical and medical product suppliers in the respective subject, mainly from "high-cost and / or high-volume" products.
Publication: Rapid Assessment 7a: https://eprints.aihta.at/1053
Contact: Claudia Wild
Newsletter
Note: this content is only available in German.
Inhalt
Newsletter
Note: this content is only available in German.
Inhalt
Announcement
Vaccination against human papillomavirus (HPV). Decision-aid for young women and girls
In 2008 the German AOK-Bundesverband commissioned the LBI-HTA to develop a decision-aid on the vaccination against Human Papillomavirus (HPV) for young women and girls (online since June 2009). After smaller updates in 2010 and 2011, the updated, completely revised and partly new structured decision-aid went online in March 2015 (www.hpv-entscheidungshilfe.de).The first part of the decision aid contains information about the virus and HPV related diseases. The second part of the decision aid informs about the HPV-vaccine(s). Finally, the third part of the decision aid summarises information of parts I and II: eleven short information blocks can be rated according to the relevance for the decision (mainly pro or mainly contra vaccination or of no influence). In the present project report online contents are available in paper form for the first time. Hence, we were able to add country specific data for Austria and provide further, more detailed information (which has not been included in the online version due to complexity).
Publication: Decision Support Document No. 79: https://eprints.aihta.at/1050
Contact: Brigitte Piso
Announcement
Horizon Scanning in Onkology - Reports
We are pleased to introduce our new HSO report.
DSD HSO No. 50
Nivolumab (Opdivo®) as single-agent first-line therapy for unresectable or metastatic melanoma
Newsletter
Note: this content is only available in German.
Inhalt
Project / High tech medicine, European collaboration
HTA Strategy for Lithuania
Project leaders: Claudia Wild
Project team: Claudia Wild, Tarquin Mittermayr
Duration: February 2015 - July 2015
Publication: HTA Decision Support Document No. 90a: https://eprints.aihta.at/1064/
Newsletter
Note: this content is only available in German.
Inhalt
Announcement
Hadron therapy in children: evidence synthesis for 15 paediatric tumours. Report based on Belgian (KCE) HTA report
A Belgian KCE-Assessment analysed – as an update of the 2007 report – the evidence for hadron therapy (proton and carbon ions) in 15 paediatric indications. Since 2015 the Austrian MedAustron started operating and the first patients are treated, the LBI -HTA has been involved in the Belgian report as external expert. Now the LBI -HTA wrote – due to the regional relevance – a German summary of the Belgian report.
In the assessment 21 clinical studies (non-randomized, non-controlled and mostly retrospective) were found. All studies showed serious methodological flaws. The conclusion therefore is that to date clinical data on PBT in all paediatric cancers under study are lacking as well as critical information on long-term effectiveness and harms.
Prospective comparative clinical trials in the field are urgently needed.
Publication: Decision Support Document Nr. 88: https://eprints.aihta.at/1049
Contact: Claudia Wild
